Prognostic role of hydronephrosis in the treatment of patients with locally advanced cervical cancer: a retrospective cohort

• Published in: International journal of gynecological cancer Vol. 32; no. 9; pp. 1123 - 1128
• Main Authors: Nóbrega, Leandro, Zanon, Jeferson Rodrigo, Andrade, Carlos e Eduardo Mattos da Cunha, Schmidt, Ronaldo Luis, dos Santos, Marcelo Henrique, Dos Reis, Ricardo
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.09.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Cancer therapies; Cervical cancer; Chemotherapy; Creatinine; Hydronephrosis; Lymphatic system; Medical prognosis; Original Research; Ostomy; Radiation therapy; Statistical analysis; surgical procedures, operative; ureter; uterine cervical neoplasms; Variance analysis; Womens health; ureter; uterine cervical neoplasms; surgical procedures, operative
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-2022-003679

BackgroundObstructive uropathy is present in almost 50% of patients with advanced cervical cancer and is associated with worse outcomes.ObjectiveTo estimate the prognostic role of hydronephrosis and the impact of ureteral obstruction resolution in patients with locally advanced cervical cancer undergoing treatment.MethodsA retrospective cohort study was conducted of patients with International Federation of Gynecology and Obstetrics 2018 stage IIIB to IVA treated in a tertiary oncologic referral center in Brazil between January 2009 and June 2018. Three different groups were evaluated: (I) without hydronephrosis, (II) with hydronephrosis and urinary diversion, and (III) with hydronephrosis but no urinary diversion. Kaplan-Meier curves and log-rank tests estimated overall survival and progression-free survival based on the presence of hydronephrosis and urinary diversion. Clinicopathological variables were evaluated using univariate and multivariate Cox proportional hazard regression model for overall survival and progression-free survival.ResultsA total of 151 patients were evaluated: group I – 62 (41.1%); II – 44 (29.1%), and III – 45 (29.8%). Stage, histological type or grade, tumor size, parametrial or lymph node involvement were not statistically different between groups. Group I had more favorable overall survival than groups II (p<0.003) and III (p<0.02); however, no difference was noted between groups II and III. Progression-free survival was similar between groups (log-rank test p=0.95). Univariate analysis revealed hydronephrosis (p=0.002) and concurrent chemoradiotherapy (p<0.001) as a prognostic factor for worse overall survival; while tumor size (p=0.023), pelvic lymphadenopathy (p=0.015), and histological type (p=0.03) were associated with worse progression-free survival. On multivariate analysis, hydronephrosis remained as an independently associated factor with worse overall survival (HR=2.06; 95% CI 1.12 to 3.79, p=0.02).ConclusionPatients with locally advanced cervical cancer with hydronephrosis had lower overall survival even after controlling for potential confounding factors, but no difference in progression-free survival. Urinary diversion showed no impact on overall survival or progression-free survival.